Zurich, 4 January 2023
Bruker Corporation, a NASDAQ-listed US tech company, has entered into a partnership with Swiss firm Biognosys AG to deliver advanced proteomics CRO services for US biopharma and biomarker customers. As part of the partnership, Bruker has made a majority-ownership investment in Biognosys AG. Biognosys is a leader in the development of proteomics technologies and solutions for pharmaceutical and biotech research. The strategic partnership is expected to create unique synergies between Biognosys’ portfolio of proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the US. Details of the transaction were not disclosed.
An international CMS team headed by Stefan Brunnschweiler and Dr Hendrik Hirsch advised Bruker on all legal aspects of the transaction. Bruker has also relied on the expertise of CMS in the past. Previous work by CMS for Bruker Corporation included providing legal advice on the company’s investment in PreOmics.
CMS Switzerland
- Stefan Brunnschweiler, Lead Partner, Zurich, Corporate / M&A
- Andrea Relly, Senior Associate, Corporate / M&A
- Samuel Felix Gang, Senior Associate, Corporate / M&A
- Pascal Stocker, Senior Associate, Corporate / M&A
- Anna Mast, Associate, Corporate / M&A
- Dr Simone Brauchbar Birkhäuser, Partner, Intellectual Property
- Mark Cagienard, Partner, Tax
- Sarah Keller, Senior Associate, Employment & Pensions
- Hadi Mirzai, Senior Associate, Life Sciences and Competition
- Valentina Balaj, Associate, Regulatory / Compliance
CMS Germany
- Dr Hendrik Hirsch, Lead Partner, Frankfurt/Main, Corporate/M&A
- Dr Berrit Roth-Mingram, Senior Associate, Frankfurt/Main, Corporate/M&A
- Dr Thomas Hirse, Partner, Dusseldorf, Intellectual Property
- Sven Krause, Senior Associate, Dusseldorf, Intellectual Property
